Kasia Kozlowski
YOU?
Author Swipe
View article: Somatostatin Receptor Imaging with [<sup>18</sup>F]FET-βAG-TOCA PET/CT and [<sup>68</sup>Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study
Somatostatin Receptor Imaging with [<sup>18</sup>F]FET-βAG-TOCA PET/CT and [<sup>68</sup>Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study Open
There is a clinical need for 18F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [68Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility…
View article: Bench to Bedside Development of [18F]Fluoromethyl-(1,2-2H4)choline ([18F]D4-FCH)
Bench to Bedside Development of [18F]Fluoromethyl-(1,2-2H4)choline ([18F]D4-FCH) Open
Malignant transformation is characterised by aberrant phospholipid metabolism of cancers, associated with the upregulation of choline kinase alpha (CHKα). Due to the metabolic instability of choline radiotracers and the increasing use of l…
View article: Clinical translation of 18F-fluoropivalate – a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers
Clinical translation of 18F-fluoropivalate – a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers Open
Background Fatty acids derived de novo or taken up from the extracellular space are an essential source of nutrient for cell growth and proliferation. Radiopharmaceuticals including 11 C-acetate, and 18 F-FAC (2- 18 F-fluoroacetate), have …
View article: Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [<sup>18</sup>F]fluoromethyl-(1,2-<sup>2</sup>H<sub>4</sub>)-choline
Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [<sup>18</sup>F]fluoromethyl-(1,2-<sup>2</sup>H<sub>4</sub>)-choline Open
Purpose: The spatio-molecular distribution of choline and its metabolites in tumors is highly heterogeneous. Due to regulation of choline metabolism by hypoxic transcriptional signaling and other survival factors, we envisage that d…
View article: Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer
Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer Open
View article: Histogram analysis of apparent diffusion coefficient from whole-body diffusion-weighted MRI to predict early response to chemotherapy in patients with metastatic colorectal cancer: preliminary results
Histogram analysis of apparent diffusion coefficient from whole-body diffusion-weighted MRI to predict early response to chemotherapy in patients with metastatic colorectal cancer: preliminary results Open
View article: Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer Open
View article: Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer Open
View article: Clinical Translation of a Click-Labeled <sup>18</sup>F-Octreotate Radioligand for Imaging Neuroendocrine Tumors
Clinical Translation of a Click-Labeled <sup>18</sup>F-Octreotate Radioligand for Imaging Neuroendocrine Tumors Open
The favorable safety, imaging, and dosimetric profile makes (18)F-FET-βAG-TOCA a promising candidate radioligand for staging and management of NETs. Clinical studies in an expanded cohort are ongoing to clinically qualify this agent.
View article: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer Open
ClinicalTrials.gov: NCT01290354.